Rare diseases

New evidence for abatacept in RA-ILD could be practice changing 

New evidence for the use of abatacept in the treatment of interstitial lung disease (ILD) associated with RA has the potential to be practice changing, rheumatologists say. A multicentre observational study of 263 patients with RA-ILD has found stable or improved pulmonary function tests in ~90% of the patients who were treated with abatacept. Furthermore, ...

Already a member?

Login to keep reading.

© 2021 the limbic